IOVA
Iovance Biotherapeutics Inc
Halal Rating :
Last Price
$5.92
Last updated:
Market Cap
-
7D Change
2.42%
1 Year Change
-26.73%
Company Overview
Industries
Exchange
Next Earnings Date
Iovance Biotherapeutics Inc is a late-stage biotechnology company focused on developing and commercializing cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology. The company's lead product candidate, lifileucel, is being developed for the treatment of metastatic melanoma and other solid tumors.
The company is primarily engaged in research and development activities and recently began commercial operations with their first FDA-approved product AMTAGVI™ for advanced melanoma.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $58.55m | $147.62m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $31.11m | $133.02m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $715000.0 | $118.44m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Iovance Biotherapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.